Androgen receptor activation: a prospective therapeutic target for bladder cancer?

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Jakse G, Hall R, Bono A, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU group phase II protocol 30861. Eur Urol. 2001;40:144–150.
   PubMed Web of Science ®Google Scholar
• Ghosh M, Brancato SJ, Agarwal PK, et al. Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014;26:305–320.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;65:7–30.
   Web of Science ®Google Scholar
• Scosyrev E, Noyes K, Feng C, et al. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009;115:68–74.
   PubMed Web of Science ®Google Scholar
• Ugnat AM, Luo W, Semenciw R, et al. Occupational exposure to chemical and petrochemical industries and bladder cancer risk in four western Canadian provinces. Chronic Dis Can. 2004;25:7–15.
   PubMedGoogle Scholar
• Siegel RL, Jacobs EJ, Newton CC, et al. Deaths due to cigarette smoking for 12 smoking-related cancers in the United States. JAMA Intern Med. 2015;175:1574–1576.
   PubMed Web of Science ®Google Scholar
• Hartge P, Harvey EB, Linehan WM, et al. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst. 1990;82:1636–1640.
   PubMed Web of Science ®Google Scholar
• Hemelt M, Yamamoto H, Cheng KK, et al. The effect of smoking on the male excess of bladder cancer: a meta-analysis and geographical analyses. Int J Cancer. 2009;124:412–419.
   PubMed Web of Science ®Google Scholar
• Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276–308.
   PubMed Web of Science ®Google Scholar
• Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res. 2004;10:2208–2219.
   PubMed Web of Science ®Google Scholar
• Singer EA, Golijanin DJ, Miyamoto H, et al. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother. 2008;9:211–228.
   PubMed Web of Science ®Google Scholar
• Chen Z, Lan X, Thomas-Ahner JM, et al. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. Embo J. 2015;34:502–516.
   PubMed Web of Science ®Google Scholar
• Knudsen K, Penning T. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 2010;21:315–324.
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99:558–568.
   PubMed Web of Science ®Google Scholar
• Zhuang YH, Bläuer M, Tammela T, et al. Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology. 1997;30:556–562.
   PubMed Web of Science ®Google Scholar
• Ide H, Miyamoto H. Steroid hormone receptor signals as prognosticators for urothelial tumor. Dis Markers. 2015;2015:840640.
   PubMed Web of Science ®Google Scholar
• Kashiwagi E, Fujita K, Yamaguchi S, et al. Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. Cancer Biol Ther. 2016;17:1188–1196.
   PubMed Web of Science ®Google Scholar
• Birtle AJ, Freeman A, Munson P. The androgen receptor revisited in urothelial carcinoma. Histopathology. 2004;45:98–99.
   PubMed Web of Science ®Google Scholar
• Tuygun C, Kankaya D, Imamoglu A, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol. 2011;29:43–51.
   PubMed Web of Science ®Google Scholar
• Mashhadi R, Pourmand G, Kosari F, et al. Role of steroid hormone receptors in formation and progression of bladder carcinoma: a case-control study. Urol J. 2014;11:1968–1973.
   PubMed Web of Science ®Google Scholar
• Boorjian S, Ugras S, Mongan NP, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology. 2004;64:383–388.
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Heemers HV, Frank I, et al. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer. 2009;16:123–137.
   PubMed Web of Science ®Google Scholar
• Kauffman EC, Robinson BD, Downes MJ, et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinogen. 2011;50:931–944.
   PubMed Web of Science ®Google Scholar
• Rau KM, Chen YJ, Sun MT, et al. Prognostic effects and regulation of activin A, maspin, and the androgen receptor in upper urinary tract urothelial carcinoma. Anticancer Res. 2011;31:1713–1720.
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012;109:1716–1726.
   PubMed Web of Science ®Google Scholar
• Shyr CR, Chen CC, Hsieh TF, et al. The expression and actions of androgen receptor in upper urinary tract urothelial carcinoma (UUTUC) tissues and the primary cultured cells. Endocrine. 2013;43:191–199.
   PubMed Web of Science ®Google Scholar
• Nam JK, Park SW, Lee SD, et al. Prognostic value of sex-hormone receptor expression in non-muscle-invasive bladder cancer. Yonsei Med J. 2014;55(5):1214–1221.
   PubMed Web of Science ®Google Scholar
• Williams EM, Higgins JP, Sangoi AR, et al. Androgen receptor immunohistochemistry in genitourinary neoplasms. Int Urol Nephrol. 2015;47:81–85.
   PubMed Web of Science ®Google Scholar
• Mir C, Shariat SF, Van Der Kwast TH, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2011;108:24–30.
   PubMed Web of Science ®Google Scholar
• Jing Y, Cui D, Guo W, et al. Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition. Cancer Lett. 2014;348:135–145.
   PubMed Web of Science ®Google Scholar
• Neumeister VM, Anagnostou V, Siddiqui S, et al. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst. 2012;104:1815–1824.
   PubMed Web of Science ®Google Scholar
• Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer. 1972;8:587–594.
   PubMed Web of Science ®Google Scholar
• Okajima E, Hiramatsu T, Iriya K, et al. Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol Res. 1975;3:73–79.
   PubMed Web of Science ®Google Scholar
• Imada S, Akaza H, Ami Y, et al. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol. 1997;31:360–364.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xu Q, Huang X, et al. The effects of early versus delayed castration targeting androgen on prolonging survival in a mouse model of bladder cancer. Int J Clin Exp Pathol. 2015;8:10283–10293.
   PubMed Web of Science ®Google Scholar
• Hsu JW, Hsu IW, Xu D, et al. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am J Pathol. 2013;182:1811–1820.
   PubMed Web of Science ®Google Scholar
• Yang Z, Chang YJ, Yu IC, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med. 2007;13:348–353.
   PubMed Web of Science ®Google Scholar
• Johnson DT, Hooker E, Luong R, et al. Conditional expression of the androgen receptor increases susceptibility of bladder cancer in mice. Plos One. 2016;11:e0148851.
   PubMed Web of Science ®Google Scholar
• Lin C, Yin Y, Stemler K, et al. Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium. Cancer Res. 2013;73:5914–5925.
   PubMed Web of Science ®Google Scholar
• Shiota M, Yokomizo A, Takeuchi A, et al. Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy. Oncotarget. 2015;6:14710–14719.
   PubMed Web of Science ®Google Scholar
• Izumi K, Taguri M, Miyamoto H, et al. Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget. 2014;5:12665–12674.
   PubMed Web of Science ®Google Scholar
• Izumi K, Ito Y, Miyamoto H, et al. Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. Oncotarget. 2016;7:14153–14160.
   PubMed Web of Science ®Google Scholar
• Shiota M, Kiyoshima K, Yokomizo A, et al. Suppressed recurrent bladder cancer after androgen suppression with androgen-deprivation therapy or 5α-reductase inhibitor. J Urol. 2017;197:308–313.
   PubMed Web of Science ®Google Scholar
• Morales EE, Grill S, Svatek RS, et al. Finasteride reduces risk of bladder cancer in a large prospective screening study. Eur Urol. 2016;69:407–410.
   PubMed Web of Science ®Google Scholar
• Imaoka S, Yoneda Y, Sugimoto T, et al. Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcription-polymerase chain reaction. Cancer Lett. 2001;166:119–123.
   PubMed Web of Science ®Google Scholar
• Izumi K, Li Y, Ishiguro H, et al. Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen. Mol Carcinogen. 2014;54:314–324.
   Web of Science ®Google Scholar
• Izumi K, Zheng Y, Hsu JW, et al. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinogen. 2013;52:94–102.
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Klaene JJ, Li Y, et al. The inverse relationship between bladder and liver in 4-aminobiphenyl-induced DNA damage. Oncotarget. 2015;6:836–845.
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Izumi K, Yao JL, et al. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor. Hum Pathol. 2012;43:2033–2040.
   PubMed Web of Science ®Google Scholar
• Li Y, Ishiguro H, Kawahara T, et al. GATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgens. Am J Cancer Res. 2014;4:461–473.
   PubMed Web of Science ®Google Scholar
• Chen F, Langenstroer P, Zhang G, et al. Androgen dependent regulation of BCG induced IL6 expression in human transitional carcinoma cell lines. J Urol. 2003;170:2009–2013.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Izumi K, Yao JL, et al. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer. 2011;18:451–464.
   PubMed Web of Science ®Google Scholar
• Overdevest JB, Knubel KH, Duex JE, et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci USA. 2012;109:E3588–96.
   PubMed Web of Science ®Google Scholar
• Kawahara T, Shareef HK, Aljarah AK, et al. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression. Oncotarget. 2015;6:29860–29876.
   PubMed Web of Science ®Google Scholar
• Kawahara T, Ide H, Kashiwagi E, et al. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. Urol Oncol. 2016;34:432.e15-23.
   PubMed Web of Science ®Google Scholar
• Izumi K, Zheng Y, Li Y, et al. Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor. Int J Oncol. 2012;41:1587–1592.
   PubMed Web of Science ®Google Scholar
• Shiota M, Takeuchi A, Yokomizo A, et al. Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. J Urol. 2012;188:276–286.
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng Y, Izumi K, et al. Androgen activates beta-catenin signaling in bladder cancer cells. Endocr Relat Cancer. 2013;20:293–304.
   PubMed Web of Science ®Google Scholar
• Ding G, Yu S, Cheng S, et al. Androgen receptor (AR) promotes male bladder cancer cell proliferation and migration via regulating CD24 and VEGF. Am J Transl Res. 2016;8:578–587.
   PubMed Web of Science ®Google Scholar
• Hsieh TF, Chen CC, Ma WL, et al. Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation. Oncol Rep. 2013;30:2917–2922.
   PubMed Web of Science ®Google Scholar
• Wu JT, Han BM, Yu SQ, et al. Androgen receptor is a potential therapeutic target for bladder cancer. Urology. 2010;75:820–827.
   PubMed Web of Science ®Google Scholar
• Jitao W, Jinchen H, Qingzuo L, et al. Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition. Andrologia. 2014;46:1128–1133.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ishiguro H, Ide H, et al. Compound A inhibits bladder cancer growth predominantly via glucocorticoid receptor transrepression. Mol Endocrinol. 2015;29:1486–1497.
   PubMed Web of Science ®Google Scholar
• Johnson AM, O’Connell MJ, Miyamoto H, et al. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urol. 2008;8:7.
   PubMedGoogle Scholar
• Garcia Del Muro X, Torregrosa A, Muñoz J, et al. Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer. Eur J Cancer. 2000;36:357–362.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Murray S, Kyriakou F, et al. Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for wnt pathway implication. Int J Cancer. 2009;124:103–108.
   PubMed Web of Science ®Google Scholar
• Thomas S, Harding MA, Smith SC, et al. CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res. 2012;72:5600–5612.
   PubMed Web of Science ®Google Scholar
• Agarwal N, Dancik GM, Goodspeed A, et al. GON4L drives cancer growth through a YY1-androgen receptor-CD24 axis. Cancer Res. 2016;76:5175–5185.
   PubMed Web of Science ®Google Scholar
• Kawahara T, Ide H, Kashiwagi E, et al. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation. Am J Cancer Res. 2015;5:2959–2968.
   PubMed Web of Science ®Google Scholar
• Wu J, Liu J, Jia R, et al. Nur77 inhibits androgen-induced bladder cancer growth. Cancer Invest. 2013;31:654–660.
   PubMed Web of Science ®Google Scholar
• Lin C, Lin W, Yeh S, et al. Infiltrating neutrophils increase bladder cancer cell invasion via modulation of androgen receptor (AR)/MMP13 signals. Oncotarget. 2015;6:43081–43089.
   PubMed Web of Science ®Google Scholar
• Ou Z, Wang Y, Liu L, et al. Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals. Oncotarget. 2015;6:26065–26078.
   PubMed Web of Science ®Google Scholar
• Tao L, Qiu J, Jiang M, et al. Infiltrating T cells promote bladder cancer progression via increasing IL1androgen receptorHIF1αVEGFa signals. Mol Cancer Ther. 2016;15:1943–1951.
   PubMed Web of Science ®Google Scholar
• Kashiwagi E, Ide H, Inoue S, et al. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. Oncotarget. 2016;7:49169–49179.
   PubMed Web of Science ®Google Scholar
• Jalalizadeh M, Smith AK, Miyamoto H. Intravesical bacillus Calmette-Guérin therapy for bladder cancer: molecular mechanisms of action. Clin Immunol Endocr Metab Drugs. 2016;3:31–38.
   Google Scholar
• Shang Z, Li Y, Zhang M, et al. Antiandrogen therapy with hydroxyflutamide or androgen receptor degradation enhancer ASC-J9 enhances BCG efficacy to better suppress bladder cancer progression. Mol Cancer Ther. 2015;14:2586–2594.
   PubMed Web of Science ®Google Scholar
• Niu Y, Chang TM, Yeh S, et al. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene. 2010;29:3593–3604.
   PubMed Web of Science ®Google Scholar
• Wu S, Lv Z, Zhu J, et al. Somatic mutation of the androgen receptor gene is not associated with transitional cell carcinoma: a “negative” study by whole-exome sequencing analysis. Eur Urol. 2013;64:1018–1019.
   PubMed Web of Science ®Google Scholar